HR+/HER2-NEGATIVE BREAST CANCER
Clinical trials for HR+/HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to tame breast cancer and blood sugar spikes
Disease control Recruiting nowThis study tests a new drug, evexomostat, added to two standard treatments for a common type of advanced breast cancer (HR+, HER2-). The goal is to see if the combination is safe and can reduce severe blood sugar spikes caused by the standard drugs. About 52 adults with specific …
Matched conditions: HR+/HER2-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: SynDevRx, Inc. • Aim: Disease control
Last updated May 17, 2026 06:15 UTC
-
New pill shows promise for Hard-to-Treat breast cancer in early trial
Disease control Recruiting nowThis study tests a new daily pill called TOS-358 in women with a specific type of advanced breast cancer (HR+ HER2-) that has a PIK3CA gene change. The main goals are to find the best dose and see if it is safe when taken alone or with standard treatments. About 241 adults will t…
Matched conditions: HR+/HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Totus Medicines • Aim: Disease control
Last updated May 15, 2026 11:54 UTC